Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202927 | 0.80 | ALDH1A1 (0.46) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL31571463 | 0.80 | GPR35 (0.47) | GPR35MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL1191637 | 0.80 | GPR35 (0.47) | GPR35MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL29467174 | 0.80 | ALDH1A1 (0.46) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL8075138 | 0.78 | ALDH1A1 (0.45) | GPR35MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL801406 | 0.78 | SMN1; SMN2 (0.50) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL31092297 | 0.78 | SMN1; SMN2 (0.50) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL203785 | 0.77 | MEN1 (0.41) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL8565505 | 0.77 | MAPT (0.45) | GPR35MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL541578 | 0.77 | ALDH1A1 (0.50) | MAPTKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630419-A1 | NOVEL SUBSTITUTED PYRAZINE-CARBOXAMIDE-IMIDAZOPYRIDINE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121367-A1 | NOVEL SUBSTITUTED PYRAZINE-CARBOXAMIDE-IMIDAZOPYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-13 | — | — | WO | disclosed |
| CN-108368127-B | Compounds and their use as EP4 receptor antagonists | 武田药品工业株式会社 | 2020-12-11 | — | — | CN | disclosed |
| US-20200339577-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-29 | — | — | US | disclosed |
| US-10745397-B2 | 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-18 | — | — | US | disclosed |
| EP-3325490-B1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2019-12-18 | — | — | EP | disclosed |
| CN-108368127-A | 1,2,3,4- tetrahydrochysene -1,7- naphthyridines -8- the amine derivatives of 1- substitutions and its purposes as EP4 receptor antagonists | 武田药品工业株式会社 | 2018-08-03 | — | — | CN | disclosed |
| US-20180215754-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-02 | — | — | US | disclosed |
| EP-3325490-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| EP-2285786-A1 | QUINOXALINEDIONE DERIVATIVES | Merck Patent GmbH (DE) | 2011-02-23 | — | — | EP | disclosed |
| WO-2010089773-A2 | PROCESS FOR PREPARATION OF NITROPYRIDINE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010089773-A2 | PROCESS FOR PREPARATION OF NITROPYRIDINE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2010-08-12 | — | — | WO | disclosed |
| WO-2009152909-A1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-23 | — | — | WO | disclosed |
| WO-2005121094-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTI-HIV-AGENTS | PFIZER LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
| US-20040063761-A1 | 2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridine derivatives | KUDUK SCOTT D (US) | 2004-04-01 | — | — | US | disclosed |
| US-20040044041-A1 | 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives | KUDUK SCOTT D (US) | 2004-03-04 | — | — | US | disclosed |
| US-20040034064-A1 | 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives | KUDUK SCOTT D (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040029920-A1 | 2-(biarylalkyl)amino-3-(heterocyclylcarbonylamino)-pyridine derivatives | KUDUK SCOTT D (US) | 2004-02-12 | — | — | US | disclosed |
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029920-A1 | 2-(biarylalkyl)amino-3-(heterocyclylcarbonylamino)-pyridine derivatives | BDKRB1, BDKRB2, LTB4R2 | GPR35 560/4885MAPT 3217/4885KDM4E 4302/4885 |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | GPR35 3721/4885MAPT 4377/4885KDM4E 2117/4885 |
| US-10745397-B2 | 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists | PTGER4, PTGER1, PTGER3 | GPR35 369/4885MAPT 3480/4885KDM4E 2520/4885 |
| US-20200339577-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | GPR35 369/4885MAPT 3480/4885KDM4E 2520/4885 |
| US-20040063761-A1 | 2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridine derivatives | BDKRB1, BDKRB2, LTB4R2 | GPR35 465/4885MAPT 3513/4885KDM4E 4402/4885 |
| US-20030225131-A1 | Thrombin inhibitors | TFPI, SERPINC1, PLAT | GPR35 2371/4885MAPT 3769/4885KDM4E 2998/4885 |
| US-20180215754-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | GPR35 369/4885MAPT 3480/4885KDM4E 2520/4885 |
| US-20040044041-A1 | 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives | BDKRB1, BDKRB2, LTB4R2 | GPR35 540/4885MAPT 3876/4885KDM4E 4426/4885 |
| US-20040034064-A1 | 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives | BDKRB1, BDKRB2, LTB4R2 | GPR35 406/4885MAPT 3397/4885KDM4E 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.